


C1: Cohort 1; C2: Cohort 2; R: randomization; Schedule of Activities (SoA)

FIG. 1



RR in lesions,(1) % (95% CI):
-56.2 (-194.0–17.1)
-62.8 (-356.2–41.9)
13.5 (-126.1–66.9)
85.0 (28.0–96.9)
Mean number of lesions, n (SD)
6.0
4.5
3.0
1.5
0.0
1.03
1.39
0.77
0.76
0.13
Placebo
5 mg
15 mg
30 mg
60 mg
BTKi
Analysis Group
# of patients
59
31
31
33
31

FIG. 2A




FIG. 2B



RR in lesions,(1) % (95% CI):
10.2 (-86.5–56.7)
37.1 (-38.1–71.3)
38.5 (-56.6–75.9)
89.3 (68.4–96.4)
Mean number of lesions, n (SD)
9.0
7.5
6.0
4.5
3.0
1.5
0.0
2.12
1.90
1.32
1.30
0.23
Placebo
5 mg
15 mg
30 mg
60 mg
BTKi
Analysis Group
# of patients
59
31
31
33
31

FIG. 3A




FIG. 3B




FIG. 4



Naive mouse microglia
**
CTL
BTKi
RQ (relative expression)
1.6
1.4
1.2
1.0
0.8

FIG. 5B



RNA-seq Rgs1 mRNA
CTL
IgG
IgG+BTKi
FPKM (Log2)
7.0
6.8
6.6
6.4
6.2
6.0
5.8

FIG. 5A



Mouse brain
mRNA
RQ (relative expression)
2.0
1.5
1.0
0.5
0.0
veh
0.6
6
24
BTKi (mg/kg)
**
**

FIG. 6




FIG. 7B



FIG. 7A